Ticagrelor is well tolerated in single doses up to 900 mg. Gastrointestinal toxicity was dose-limiting in a single ascending dose study. Other clinically meaningful adverse reactions which may occur with overdose include dyspnoea and ventricular pauses (see Adverse Reactions).
In the event of overdose, the above potential adverse reactions could occur and ECG monitoring should be considered.
There is currently no known antidote to reverse the effects of Brilinta, and Brilinta is not expected to be dialysable (see Precautions). Treatment of overdose should follow local standard medical practice. The expected effect of excessive Brilinta dosing is prolonged duration of bleeding risk associated with platelet inhibition. If bleeding occurs appropriate supportive measures should be taken.